FAIRFIELD, Conn., June 4, 2010 (GLOBE NEWSWIRE) -- Competitive Technologies, Inc. (NYSE Amex:CTT) announced today that the Walter Reed Army Medical Center in Washington, D.C., has joined the growing list of organizations that will treat pain patients with CTT's Calmare® Pain Therapy Treatment, as authorized by the Surgeon General of the U.S. Army and Commanding General of the U.S. Army Medical Command. The Calmare Pain Therapy Treatment will be used to treat wounded warriors and other military personnel who are suffering from neuropathic pain.
"We are pleased to have this opportunity to make a difference in the lives of those who have given so much in defense of our great nation," said John B. Nano, CTT's Chairman, President and CEO. "With over 60% of our returning veterans suffering from significant pain, as reported at last month's American Pain Society annual meeting, we are glad to be able to offer these wounded warriors and their physicians a non-invasive pain relief option without the harmful, adverse side effects associated with powerful opioids, such as morphine. Calmare Pain Therapy successfully treats chronic neuropathic pain resulting from phantom limb syndrome, shingles, failed back surgery, sciatica, spinal stenosis and other maladies."
"As a veteran, I am thrilled to see Walter Reed Army Medical Center added to the growing number of respected medical institutions treating patients with CTT's Calmare Pain Therapy," said Jean Wilczynski of IR Services, LLC. "I believe it is of utmost importance that our wounded warriors and service members suffering from serious injuries and severe, debilitating pain be provided with the best possible treatment options, especially those that can help them avoid the harmful side effects of powerful opioids and other medications."
Calmare is currently being used at the Virginia Commonwealth University Massey Cancer Center, the Paul Carbone Cancer Center at the University of Wisconsin, Madison, and the University of Miami Pain Management Center. Calmare is also being used to treat international patients in Italy, India, Greece, Bangladesh, and U.S. patients at clinics in Massachusetts, New York, Virginia, Florida, Connecticut and Rhode Island.
The non-invasive Calmare pain therapy device uses the biophysical "Scrambler Therapy" technology, which was developed in Italy by CTT's client, Professor Giuseppe Marineo. CTT's partner, GEOMC Co. Ltd. of Seoul, Korea is currently manufacturing the Calmare device, which has U.S. FDA clearance and European Union CE Mark clearance for sales. For more information on the device, visit www.calmarett.com.
About Walter Reed Army Medical Center
The Walter Reed Army Medical Center is the hub of the Walter Reed Health Care System and provides comprehensive health care to more than 150,000 Service Members, retirees and their families. Walter Reed Army Medical Center is the largest Department of Defense military hospital serving the military community from the Washington area and around the world. For more information, visit www.wramc.army.mil.
About Competitive Technologies, Inc.
Competitive Technologies, established in 1968, provides distribution, patent and technology transfer, sales and licensing services focused on the needs of its customers and matching those requirements with commercially viable product or technology solutions. CTT is a global leader in identifying, developing and commercializing innovative products and technologies in life, electronic, nano, and physical sciences developed by universities, companies and inventors. CTT maximizes the value of intellectual assets for the benefit of its customers, clients and shareholders. Visit CTT's website: www.competitivetech.net
Statements made about our future expectations are forward-looking statements and subject to risks and uncertainties as described in our most recent Annual Report on Form 10-K for the year ended July 31, 2008, filed with the SEC on October 28, 2008, and other filings with the SEC, and are subject to change at any time. Our actual results could differ materially from these forward-looking statements. We undertake no obligation to update publicly any forward-looking statement.